TERN
Terns Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow +30.0% ·
net new positions -10.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 105 | +14 | 70.88M | $3.72B | +22 | −9 |
| Q4 2025 | 91 | +4 | 71.76M | $2.90B | +5 | — |
| Q3 2025 | 16 | 0 | 30.56M | $229.52M | — | — |
| Q2 2025 | 13 | 0 | 20.60M | $76.83M | +2 | −2 |
| Q1 2025 | 10 | -3 | 10.19M | $28.12M | — | −3 |
| Q4 2024 | 13 | +2 | 13.10M | $72.60M | +2 | — |
| Q3 2024 | 10 | -1 | 11.63M | $97.00M | — | −1 |
| Q2 2024 | 11 | — | 7.84M | $53.39M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 3.67M | +151.6% | $30.63M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 3.67M | +151.6% | $30.63M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 2.71M | +0.6% | $22.58M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 4 | Millennium Management ✦ | 1.58M | +38.4% | $13.16M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.48M | +5430.4% | $12.31M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.48M | +5430.4% | $12.31M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 1.21M | +7.6% | $10.07M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 1.21M | +7.6% | $10.07M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 479.50K | +448.0% | $4.00M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 222.06K | -0.9% | $1.85M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 222.06K | -0.9% | $1.85M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 144.26K | +134.9% | $1.20M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 104.76K | +303.1% | $873,682 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Marshall Wace ✦ | 104.76K | +303.1% | $873,682 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 37.47K | +39.0% | $312,508 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 37.47K | +39.0% | $312,508 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Adage Capital Partners | $6.64M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 314 holders, 121.84M shares, $6.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.